Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEMTX versus no treatment after curative resection for stage II-III gastric or distal oesophageal adenocarcinoma
ISRCTN71625775Phase 3Completed
- Sponsor
- Pharmacia
- Start
- Jan 1993
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of methotrexate, fluorouracil, epirubicin and folinic acid in gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Pharmacia. Started Jan 1993; status: completed.
02
Drugs
methotrexatefluorouracilepirubicinfolinic acid
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ISRCTN71625775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71625775.